NIH R01 · 2025
Recent changes in overdose mortality are driven by rapid increases in polysubstance-involved deaths, most often including opioids followed by stimulants. Prior studies have found important individual (e.g., comorbid mental/physical health), social (e.g., family supports), and community factors (e.g., treatment availability) associated with PSU, treatment, and outcomes. However, little is known about the modifiable individual-level motivators (e.g. use to alleviate withdrawal) and preferences driving high-risk polysubstance use (PSU) behaviors (e.g., intravenous use, higher frequency of opioid-involved PSU, intentional use of synthetic opioids, and simultaneous use of substances), which is…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.